Rani Therapeutics (RANI) Q1 2026 earnings summary

Executive summary

• Clinical-stage biotherapeutics company advancing oral biologics delivery via RaniPill capsule, with two configurations targeting antibodies and peptides.

• No approved products or commercial revenue; progressing clinical pipeline and partnerships, notably with Chugai and ProGen.

• Advanced Phase 1 clinical trial of RT-114 for obesity using RaniPill in partnership with ProGen, initiated December 2025 with results expected in 2027.

• Appointed Alireza Javadi, Ph.D. as CTO, Jesper Høiland as Head of Strategy, Dr. Sara Kenkare-Mitra as Strategic Advisor, and announced CFO transition.

Financial highlights

• Contract revenue was $1.7M for Q1 2026, up from $0.2M in Q1 2025, mainly from the Chugai collaboration.

• Net loss for Q1 2026 was $8.0M, a 37% improvement from $12.7M in Q1 2025, with stock-based compensation of $2.1M.

• Research and development expenses decreased 21% year-over-year to $5.2M; general and administrative expenses decreased 13% to $4.9M.

• Cash, cash equivalents, and marketable securities totaled $43.4M as of March 31, 2026, down from $49.7M at year-end 2025.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from the reporting date, with reserves and expected Chugai milestone projected to fund into Q4 2027.

• Anticipates continued operating losses and negative cash flows as development and clinical activities progress.

• Plans to seek additional funding through equity, debt, or collaborations to support ongoing R&D and commercialization efforts.

• Management believes the company is well-positioned to execute on 2026 priorities and advance the RaniPill platform.